Loading clinical trials...
Loading clinical trials...
A Phase II Study of Pazopanib GW786034, NSC# 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors
Conditions
Interventions
Pazopanib
Locations
31
United States
Novartis Investigative Site
Long Beach, California, United States
Novartis Investigative Site
Madera, California, United States
Novartis Investigative Site
Orange, California, United States
Novartis Investigative Site
Palo Alto, California, United States
Novartis Investigative Site
San Francisco, California, United States
Novartis Investigative Site
Hartford, Connecticut, United States
Start Date
October 8, 2014
Primary Completion Date
November 5, 2019
Completion Date
November 5, 2019
Last Updated
August 12, 2020
NCT07403370
NCT06815575
NCT05770102
NCT03572192
NCT02407509
NCT05508334
Lead Sponsor
Novartis Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions